Subtype-specific mutations drive relapse risk in most common childhood leukemia

by St. Jude Children's Research Hospital

edited by Gaby Clark, reviewed by Andrew Zinin

Gaby Clark

Scientific Editor

Meet our editorial team
Behind our editorial process

Andrew Zinin

Chief Editor

Meet our editorial team
Behind our editorial process Editors' notes

This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

fact-checked

peer-reviewed publication

trusted source

proofread

The GIST Add to Preferred Sources

Some cases of the most common childhood cancer, B-cell acute lymphoblastic leukemia (B-ALL), return after treatment—and genetic changes present from the start may help explain why. Scientists at St. Jude Children's Research Hospital and Seattle Children's Hospital, in collaboration with the Children's Oncology Group, found that mutations in a patient's original tumor can be associated with relapse risk, and that these changes differ by leukemia subtype. The findings, published in Blood, could help researchers better estimate and adjust for relapse risk before treatment begins.

More than 90% of patients with B-ALL survive with modern treatments, but outcomes are worse when the disease returns, indicating a need to prevent relapse. B-ALL is already categorized into subtypes based on the genetic changes that drive the cancer, which help guide treatment. However, the researchers wanted to understand whether additional genetic features could help explain relapses and be used to better tailor therapy.

"We verified that some tumors are born more resistant to conventional therapy," said corresponding author Xiaotu Ma, Ph.D., St. Jude Department of Computational Biology. "By identifying the resistance mutations that are already present in the original tumor, we may also have found a better way to stratify patients into higher-intensity treatments to prevent those relapses from ever occurring."

The researchers uncovered these mutations by comparing the DNA from diagnosis and relapsed samples of 183 pediatric B-ALL cases, the largest study of its kind, enabling subtype-level analysis. The findings suggest that the significance of a mutation must be considered in the context of the disease's other genetic features.

"That was surprising," Ma said. "We had expected to find some mutations that universally increased risk across subtypes, but this large cohort revealed that mutations can have a subtype-specific risk."

Looking for relapse clues within leukemia subtypes

One example emerged in the ETV6::RUNX1 subtype, which is usually associated with a good prognosis. Within the subtype, the scientists discovered that patients with exon 5 of ETV6 fused with exon 4 of RUNX1 had a significantly higher risk of relapse than those with exon 5 of ETV6 fused with exon 3 of RUNX1, a dominant fusion transcript among this subtype.

"Clinically, this is important because patients with these features also relapsed faster than those without them," said first author Yuan Feng, Ph.D., St. Jude Department of Computational Biology. "In the future, information may help clinicians decide what kind of treatment protocols should be used, as quicker relapse is associated with more aggressive disease. So, a higher-intensity therapy may be called for in these patients."

The team also identified genetic markers associated with greater relapse risk in other subtypes. That collection of mutations provides a road map to better predict which patients at diagnosis are at the highest risk of recurrence.

When relapse is not relapse

The genomic comparisons also revealed that about 3% of cases classified as relapses in this cohort were not a return of the original leukemia. Instead, they looked more like new cancers, sometimes driven by a genetic predisposition or other factors.

"These events were documented as clinical relapses, but our analysis showed that biologically they were second, unrelated cancers," said co-first author Hanxia Li, Ph.D., St. Jude Department of Computational Biology. "That matters for treatment because if we know a patient has a new cancer, then they do not need a high-intensity relapse protocol; a frontline protocol with fewer long-term side effects can likely cure them."

Collectively, the findings highlight the value of examining genetic changes already present at diagnosis, rather than mutations that arise during therapy.

"Our findings open the possibility of finding clinically actionable genomic insights that can improve and protect patient well-being from initial diagnosis," Ma said. "In the future, that may help clinicians prevent relapse before it starts."

Publication details

Identifying novel genomic alterations in relapsed childhood B-ALL: a report from the Children's Oncology Group, Blood (2026).

Journal information: Blood

Key medical concepts

B Acute Lymphoblastic Leukemia

Clinical categories

OncologyPediatricsClinical geneticsChildren's health Provided by St. Jude Children's Research Hospital Who's behind this story?

Gaby Clark

MA in English, copy editor since 2021 with experience in higher education and health content. Dedicated to trustworthy science news. Full profile →

Andrew Zinin

Master's in physics with research experience. Long-time science news enthusiast. Plays key role in Science X's editorial success. Full profile →

Citation: Subtype-specific mutations drive relapse risk in most common childhood leukemia (2026, November 2) retrieved 2 November 2026 from https://medicalxpress.com/news/2026-11-subtype-specific-mutations-relapse-common.html This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.